Allston Landing, Allston, MA Allston Landing is one of the world’s largest cell-culture manufacturing plants and was approved for commercial production by the FDA in 1996. At 185,000 square feet, the manufacturing capacity of the plant is 12,000 liters of perfusion capacity. Allston Landing is responsible for the cell-culture and purification of three products: • Cerezyme® (imiglucerase for injection), an enzyme replacement therapy for Type 1 Gaucher disease. More than 4,600 patients worldwide are currently receiving Cerezyme, which was approved in the mid-1990’s. • Fabrazyme® (agalsidase beta), an enzyme replacement therapy for Fabry disease. More than 1,700 patients worldwide are currently receiving Fabrazyme. Fabrazyme was first approved in Europe in 2001 and in the United States in 2003. • Myozyme® (alglucosidase alfa), an enzyme replacement therapy product for the treatment of Pompe disease patients, an often fatal genetic disorder. Myozyme is currently under review for marketing approval by European and U.S. regulatory authorities, with anticipated launch in the first half of 2006. Genzyme also performs the filling for Thyrogen® (thyrotropin alfa) and Aldurazyme (laronidase) at Allston.